Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

Fintel reports that on January 28, 2025, BTIG initiated coverage of Arcturus Therapeutics Holdings (NasdaqGM:ARCT) with a Buy ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public skepticism. Click for my ARCT stock update.

In the assessment of 12-month price targets, analysts unveil insights for Arcturus Therapeutics, presenting an average target of $58.6, a high estimate of $63.00, and a low estimate of $41.00.

Axsome Therapeutics (AXSM) shares soared 20.2% in the last trading session to close at $127.08. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a ...

Arcturus Therapeutics (ARCT) announced the appointment of Moncef Slaoui as chair designate. Slaoui has been serving on the company’s board of ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

BTIG Research began coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) in a research report issued on Tuesday, MarketBeat reports. The brokerage set a “buy” rating and a ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Arcturus Therapeutics (NASDAQ:ARCT) in the last three months. The table below summarizes ...